Saltar al contenido
Merck
Todas las fotos(1)

Documentos

Y0001288

Salbutamol hemisulfate salt

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Salbutamol hemisulfate salt, α1-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol hemisulfate salt, Albuterol sulfate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C13H21NO3 · 0.5H2SO4
Número de CAS:
51022-70-9
Peso molecular:
288.35
MDL number:
MFCD00055200
UNSPSC Code:
41116107
PubChem Substance ID:
329831344
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

albuterol, salbutamol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

OS(O)(=O)=O.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c2ccc(O)c(CO)c2

InChI

1S/2C13H21NO3.H2O4S/c2*1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;1-5(2,3)4/h2*4-6,12,14-17H,7-8H2,1-3H3;(H2,1,2,3,4)

InChI key

BNPSSFBOAGDEEL-UHFFFAOYSA-N

Gene Information

human ... ADRB2(154)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Salbutamol sulfate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Referencia del producto
Descripción
Precios

PHR1053

Albuterol sulfate, Pharmaceutical Secondary Standard; Certified Reference Material

S0150000

Salbutamol hemisulfate salt, European Pharmacopoeia (EP) Reference Standard

Y0000034

Salbutamol impurity G, European Pharmacopoeia (EP) Reference Standard

Y0000030

Salbutamol impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000031

Salbutamol impurity F, European Pharmacopoeia (EP) Reference Standard

Y0000071

Salbutamol impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000032

Salbutamol impurity I, European Pharmacopoeia (EP) Reference Standard

S0100000

Salbutamol, European Pharmacopoeia (EP) Reference Standard

Y0001186

Salbutamol impurity J, European Pharmacopoeia (EP) Reference Standard

1012633

Salbutamol hemisulfate salt, United States Pharmacopeia (USP) Reference Standard

1358784

Levalbuterol hydrochloride, United States Pharmacopeia (USP) Reference Standard

1012600

Salbutamol, United States Pharmacopeia (USP) Reference Standard

1012644

Albuterol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1012655

Albuterol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1012689

Albuterol Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP451

Salbutamol, British Pharmacopoeia (BP) Reference Standard

BP302

Salbutamol hemisulfate salt, British Pharmacopoeia (BP) Reference Standard

PHR1960

Salbutamol Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2040

Albuterol Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1961

Salbutamol Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1962

Salbutamol impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

BP712

Salbutamol aldehyde impurity, British Pharmacopoeia (BP) Reference Standard

BP192

2-tert-Butylamino-1-(4-hydroxy-3-methylphenyl)ethanol sulfate, British Pharmacopoeia (BP) Reference Standard

BP852

Salbutamol impurity B, British Pharmacopoeia (BP) Reference Standard

BP704

Salbutamol ketone impurity, British Pharmacopoeia (BP) Reference Standard

PHR2106

4-[2-[(1,1-Dimethylethyl)amino]ethyl]-2-methylphenol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9050

4-[2-(tert-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol, reference material, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9071

4-[2-[Benzyl(tert-butyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

1012564

Albuterol Related Compound I, United States Pharmacopeia (USP) Reference Standard

PHR2332

Methyl5-[2-[benzyl(tert-butyl)amino]acetyl]-2-hydroxybenzoate hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Carc. 2 - Repr. 2 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

B Padhukasahasram et al.
The pharmacogenomics journal, 14(4), 365-371 (2014-01-15)
Inhaled short-acting beta-agonist (SABA) medication is commonly used in asthma patients to rapidly reverse airway obstruction and improve acute symptoms. We performed a genome-wide association study of SABA medication response using gene-based association tests. A linear mixed model approach was
Helgo Magnussen et al.
The New England journal of medicine, 371(14), 1285-1294 (2014-09-10)
Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.
Juliet M Foster et al.
The Journal of allergy and clinical immunology, 134(6), 1260-1268 (2014-07-27)
Poor adherence contributes to uncontrolled asthma. Pragmatic adherence interventions for primary care settings are lacking. To test the effectiveness of 2 brief general practitioner (GP)-delivered interventions for improving adherence and asthma control. In a 6-month cluster randomized 2 × 2
Todd A Florin et al.
JAMA pediatrics, 168(7), 664-670 (2014-05-28)
Acute bronchiolitis is the most frequent lower respiratory tract infection in infants, yet there are no effective therapies available. Current evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronchiolitis. To determine whether nebulized
Susan Wu et al.
JAMA pediatrics, 168(7), 657-663 (2014-05-28)
Bronchiolitis is one of the most common and costly respiratory diseases in infants and young children. Previous studies have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency department (ED) setting is unclear. To compare
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico